1445591-84-3

Basic information

• Product Name: C₁₈H₂₁BrFN₃O₂
• Synonyms: C₁₈H₂₁BrFN₃O₂
• CAS NO: 1445591-84-3
• Molecular Weight: 410.286
• Mol File: 1445591-84-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: C₁₈H₂₁BrFN₃O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₈H₂₁BrFN₃O₂(1445591-84-3)
• EPA Substance Registry System: C₁₈H₂₁BrFN₃O₂(1445591-84-3)

Safety Data

• Hazardous Substances Data: 1445591-84-3(Hazardous Substances Data)

Upstream product

• 1560642-96-7 C₁₇H₂₁BrFNO₄ 
• 203866-13-1 (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid 
• 203866-16-4 1-tert-butyl 2-methyl (2S,4S)-4-fluoropyrrolidine-1,2-dicarboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 

Downstream Products

• 1399843-38-9 methyl ((S)-1-((2S,4S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-fluoropyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1399843-37-8 methyl ((S)-1-((2S,4S)-4-fluoro-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1560643-02-8 C₃₀H₃₁F₄N₃O₅S 
• 1560643-05-1 C₃₅H₄₃BFN₃O₄ 
• 1560643-08-4 C₄₁H₄₈F₂N₆O₄ 
• 1560649-18-4 C₄₅H₅₄F₂N₈O₆ 
• 1560643-01-7 C₂₄H₃₃BFN₃O₄ 
• 1613055-45-0 C₄₅H₅₀F₂N₆O₄ 
• 1613055-38-1 C₃₀H₃₁F₄N₃O₅S 
• 1612854-12-2 C₅₃H₆₂F₂N₈O₇ 

Relevant articles and documents

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.